Cargando…

Circulating tumor DNA predicts survival in patients with resected high-risk stage II/III melanoma

BACKGROUND: Patients with high-risk stage II/III resected melanoma commonly develop distant metastases. At present, we cannot differentiate between patients who will recur or those who are cured by surgery. We investigated if circulating tumor DNA (ctDNA) can predict relapse and survival in patients...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lee, R J, Gremel, G, Marshall, A, Myers, K A, Fisher, N, Dunn, J A, Dhomen, N, Corrie, P G, Middleton, M R, Lorigan, P, Marais, R
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2018
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5834029/ https://www.ncbi.nlm.nih.gov/pubmed/29112704 http://dx.doi.org/10.1093/annonc/mdx717

Ejemplares similares

A randomised trial evaluating bevacizumab as adjuvant therapy following resection of AJCC stage IIB, IIC and III cutaneous melanoma: an update
por: Biswas, S, et al.
Publicado: (2008)

Plasma total cell-free DNA (cfDNA) is a surrogate biomarker for tumour burden and a prognostic biomarker for survival in metastatic melanoma patients
por: Valpione, S., et al.
Publicado: (2018)

Distinct subclonal tumour responses to therapy revealed by circulating cell-free DNA
por: Gremel, G., et al.
Publicado: (2016)

25-hydroxyvitamin D serum levels in patients with high risk resected melanoma treated in an adjuvant bevacizumab trial
por: Lipplaa, Astrid, et al.
Publicado: (2018)

Brain microenvironment-driven resistance to immune and targeted therapies in acral melanoma
por: Lee, Rebecca Jane, et al.
Publicado: (2020)

A randomized phase III study comparing dacarbazine, BCNU, cisplatin and tamoxifen with dacarbazine and interferon in advanced melanoma
por: Middleton, M R, et al.
Publicado: (2000)

Sunglasses to hide behind may also prevent melanoma of the eyes
por: Dhomen, Nathalie, et al.
Publicado: (2021)

Circulating tumour DNA monitoring and early treatment for relapse: views from patients with early-stage melanoma
por: Woof, Victoria G., et al.
Publicado: (2022)

Stroma remodeling and reduced cell division define durable response to PD-1 blockade in melanoma
por: Galvani, Elena, et al.
Publicado: (2020)

Immune-awakening revealed by peripheral T cell dynamics after one cycle of immunotherapy
por: Valpione, Sara, et al.
Publicado: (2020)

Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial
por: Corrie, P G, et al.
Publicado: (2018)

Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial
por: Corrie, P G, et al.
Publicado: (2019)

BIM mediates synergistic killing of B-cell acute lymphoblastic leukemia cells by BCL-2 and MEK inhibitors
por: Korfi, K, et al.
Publicado: (2016)

Presence of Circulating Tumor Cells Predates Imaging Detection of Relapse in Patients with Stage III Melanoma
por: Lucci, Anthony, et al.
Publicado: (2023)

Feasibility of personalized circulating tumor DNA detection in stage II and III melanoma
por: Brunsgaard, Elise K., et al.
Publicado: (2023)

Sorafenib and dacarbazine as first-line therapy for advanced melanoma: phase I and open-label phase II studies
por: Eisen, T, et al.
Publicado: (2011)

Circulating Tumour DNA in Melanoma—Clinic Ready?
por: Tivey, Ann, et al.
Publicado: (2022)

Circulating galectin-1 delineates response to bevacizumab in melanoma patients and reprograms endothelial cell biology
por: Bannoud, Nadia, et al.
Publicado: (2023)

The Impact of Surveillance Imaging Frequency on the Detection of Distant Disease for Patients with Resected Stage III Melanoma
por: Dieng, Mbathio, et al.
Publicado: (2022)

Personalized follow-up of circulating DNA in resected stage III/IV melanoma: PERCIMEL multicentric prospective study protocol
por: Geoffrois, Lionnel, et al.
Publicado: (2023)

The T cell receptor repertoire of tumor infiltrating T cells is predictive and prognostic for cancer survival
por: Valpione, Sara, et al.
Publicado: (2021)

Author Correction: The T cell receptor repertoire of tumor infiltrating T cells is predictive and prognostic for cancer survival
por: Valpione, Sara, et al.
Publicado: (2021)

The paradox-breaking panRAF plus SRC family kinase inhibitor, CCT3833, is effective in mutant KRAS-driven cancers
por: Saturno, G., et al.
Publicado: (2021)

A phase I study of extended dosing with lomeguatrib with temozolomide in patients with advanced melanoma
por: Kefford, R F, et al.
Publicado: (2009)

Preferences for Adjuvant Immunotherapy in Adults with Resected Stage III Melanoma—A Discrete Choice Experiment
por: Livingstone, Ann, et al.
Publicado: (2023)

The Proportion Cured of Patients with Resected Stage II–III Cutaneous Melanoma in Sweden
por: Eriksson, Hanna, et al.
Publicado: (2021)

Cost-Effectiveness of PET/CT Surveillance Schedules to Detect Distant Recurrence of Resected Stage III Melanoma
por: Dieng, Mbathio, et al.
Publicado: (2022)

O(6)-methylguanine-DNA methyltransferase depletion and DNA damage in patients with melanoma treated with temozolomide alone or with lomeguatrib
por: Watson, A J, et al.
Publicado: (2009)

Treatment related toxicities with combination BRAF and MEK inhibitor therapy in resected stage III melanoma
por: Homan, Morgan, et al.
Publicado: (2022)

Psychosocial predictors of outcome: time to relapse and survival in patients with early stage melanoma
por: Brown, J E, et al.
Publicado: (2000)

Pre-operative ctDNA predicts survival in high-risk stage III cutaneous melanoma patients
por: Lee, J H, et al.
Publicado: (2019)

Resistance to BRAF inhibitors induces glutamine dependency in melanoma cells
por: Baenke, Franziska, et al.
Publicado: (2015)

Investigation of female survival benefit in metastatic melanoma
por: Richardson, B, et al.
Publicado: (1999)

Health related quality of life outcomes for unresectable stage III or IV melanoma patients receiving ipilimumab treatment
por: Revicki, Dennis A, et al.
Publicado: (2012)

Ultraviolet radiation drives mutations in a subset of mucosal melanomas
por: Mundra, Piyushkumar A., et al.
Publicado: (2021)

Neoadjuvant relatlimab and nivolumab in resectable melanoma
por: Amaria, Rodabe N., et al.
Publicado: (2022)

Effects of exercise on circulating tumor cells among patients with resected stage I-III colon cancer
por: Brown, Justin C., et al.
Publicado: (2018)

Adjuvant Nivolumab versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results from CheckMate 238
por: Larkin, James, et al.
Publicado: (2023)

T cell immune awakening in response to immunotherapy is age-dependent
por: Salih, Zena, et al.
Publicado: (2022)

Completely Resected Stage III Melanoma Controversy - 15 Years of National Tertiary Centre Experience
por: Peric, Barbara, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_a9m6mt2ldi1r2v3qla3bpi93j3